Brokerages expect Alkermes Plc (NASDAQ:ALKS) to post sales of $247.52 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Alkermes’ earnings. The lowest sales estimate is $237.50 million and the highest is $263.96 million. Alkermes reported sales of $213.51 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 15.9%. The firm is expected to report its next quarterly earnings results on Wednesday, February 21st.
According to Zacks, analysts expect that Alkermes will report full year sales of $247.52 million for the current fiscal year, with estimates ranging from $852.40 million to $893.00 million. For the next year, analysts forecast that the business will report sales of $983.51 million per share, with estimates ranging from $886.40 million to $1.02 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Alkermes.
Alkermes (NASDAQ:ALKS) last issued its earnings results on Thursday, October 26th. The company reported $0.03 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.04. The firm had revenue of $217.40 million for the quarter, compared to the consensus estimate of $231.29 million. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The company’s revenue was up 20.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.09) EPS.
In other Alkermes news, SVP James M. Frates sold 20,932 shares of Alkermes stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $47.58, for a total transaction of $995,944.56. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Michael J. Landine sold 15,000 shares of Alkermes stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $48.71, for a total value of $730,650.00. Following the transaction, the senior vice president now directly owns 178,693 shares in the company, valued at $8,704,136.03. The disclosure for this sale can be found here. Insiders have sold a total of 142,624 shares of company stock worth $7,633,176 over the last ninety days. Company insiders own 5.34% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in ALKS. Toronto Dominion Bank raised its position in shares of Alkermes by 12.7% in the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after acquiring an additional 212 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Alkermes in the 3rd quarter worth about $126,000. Virtu Financial LLC bought a new position in shares of Alkermes in the 3rd quarter worth about $201,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Alkermes in the 3rd quarter worth about $214,000. Finally, Trexquant Investment LP bought a new position in shares of Alkermes in the 3rd quarter worth about $218,000. 99.20% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Alkermes (NASDAQ:ALKS) traded up $0.91 during mid-day trading on Monday, hitting $57.03. The company’s stock had a trading volume of 716,700 shares, compared to its average volume of 936,015. The firm has a market cap of $8,910.00, a P/E ratio of -51.38 and a beta of 2.13. Alkermes has a 52-week low of $46.42 and a 52-week high of $63.40. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05.
Alkermes Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.